Grail (GRAL) Stock: Why the Biotech Crashed 50% Overnight

TLDR Grail (GRAL) stock crashed ~50% after its NHS-Galleri trial failed to meet its primary endpoint. The trial of 142,000+ people did not show a statistically significant reduction in Stage III-IV cancers. A subgroup of 12 deadly cancers showed Stage IV diagnoses fall more than 20% in years two and three. Q4 loss came in [...]

The post Grail (GRAL) Stock: Why the Biotech Crashed 50% Overnight appeared first on Blockonomi.